KDC-MN-210 – Kodiac biolabs

Plain-language summaryIntrigue 66 / 100

Mirtazapine (Remeron) does not work like an SSRI at all. Rather than blocking the serotonin pump, it blocks a brake on the nerve cells that release serotonin and norepinephrine, which causes those neurons to fire more freely. It also strongly blocks the histamine receptor that controls sleep and appetite, which is why patients on it tend to sleep deeply and gain weight. Organon brought it to market in 1996. Clinicians often reach for it when a patient needs sleep restoration or has lost weight from depression, since both effects can be therapeutic in that context. The trade-off is that the same antihistamine action makes morning grogginess common at low doses, and the appetite stimulation is unwelcome for some. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Mature approved antidepressant useful as a receptor pharmacology reference but offering little research frontier value

Honestly, mirtazapine is exactly the kind of compound that made a v2 rubric necessary. It’s a real drug, with a real mechanism, real clinical data — approved by the FDA in 1996 — and that’s kind of the whole story. The literature is enormous and thoroughly settled. Theres no frontier here.

The mechanism is genuinely distinctive in its class. Rather than blocking reuptake transporters like SSRIs and SNRIs, mirtazapine antagonizes presynaptic alpha-2 autoreceptors and heteroreceptors, disinhibiting both norepinephrine and serotonin release. Concurrent 5-HT2A and 5-HT2C antagonism then steers the released serotonin preferentially to 5-HT1A receptors. On paper, thats an elegant multi-target design. In practice, the enormous H1 histamine antagonism (Ki approximately 0.14 nM, competitive with first-generation antihistamines like diphenhydramine) dominates the experimental and subjective profile. Sedation and appetite stimulation are often the main events, and that H1 load is a real confound if you’re trying to isolate the noradrenergic or serotonergic piece — you’ll be managing sleep architecture disruption and weight changes in any animal model before you get to the signal of interest.

Evidence quality and translational signal score high here, but only because mirtazapine has been an approved drug for nearly three decades with a clinical trial base measured in the thousands of patients. The Cipriani et al. 2018 network meta-analysis in the Lancet showed a modest edge in response rate relative to some comparators, confirming it’s a competent antidepressant. None of that is news. Those scores reflect clinical history, not discovery.

Where mirtazapine retains legitimate bench utility: it does appear as a reference compound in alpha-2 adrenergic receptor pharmacology and as a 5-HT2 antagonist comparator. If your program is characterizing a novel compound’s activity at those targets, mirtazapine is a reproducible, well-characterized positive control. That said, more selective probes exist for both targets — yohimbine and atipamezole for alpha-2 antagonism, ketanserin and MDL-100907 for 5-HT2A — so mirtazapine’s bench value is mostly confined to the specific context of NaSSA pharmacology or combined noradrenergic/serotonergic interaction studies, which isnt a high-traffic area right now.

The off-label angles in cancer-related anorexia-cachexia and hyperemesis gravidarum are probably the most plausible spaces where mirtazapine could attract fresh research interest, but even those are secondary-utility questions on a known compound, not mechanism discovery. We think it earns a spot in the library as a reference standard and comparator tool, not as an active research target. Reach for it when you need a known quantity, not when you’re looking for something new.

Novelty: 18
Mechanism promise: 38
In-category differentiation: 36
Evidence quality: 72
Translational signal: 68
Research bench value: 46

Rationale Mirtazapine scores well on evidence and translational signal strictly because it is a 30-year-old approved drug with a large clinical trial base, not because it represents an active research frontier. Low novelty and a fully characterized mechanism keep the overall in the low-to-mid 40s; more selective tools exist for both its alpha-2 and 5-HT2 target spaces.

Tetracyclic atypical antidepressant (NaSSA)

A noradrenergic and specific serotonergic antidepressant; a tetracyclic with strong H1 antihistamine activity producing pronounced sedation and appetite stimulation.

Abstract

Mirtazapine ((R/S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; CAS 85650-52-8; molecular formula C17H19N3; molecular weight 265.36) is a tetracyclic NaSSA (noradrenergic and specific serotonergic antidepressant) developed at Organon and approved by the FDA in 1996 under the trade name Remeron. Mechanism distinguishes the compound from the SSRI/SNRI class: rather than inhibiting transporters, mirtazapine antagonizes presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, increasing both norepinephrine and serotonin release. Concurrent 5-HT2A and 5-HT2C antagonism redirects the released serotonin preferentially to 5-HT1A receptors. Strong H1 histamine antagonism (Ki approximately 0.14 nM, comparable to first-generation antihistamines) produces sedation and weight gain, often dose-limiting at higher doses. The compound has minimal activity at muscarinic, dopaminergic, or transporter sites. Plasma half-life is 20 to 40 hours; metabolism is via CYP2D6, CYP3A4, and CYP1A2. Approved for major depressive disorder; widely used off-label for insomnia and as an appetite stimulant. Used as a reference compound in alpha-2 adrenergic and 5-HT2 receptor pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-210Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-210

Mirtazapine

Abstract

Read the full monograph